1-Year outcomes with COMBO stents in small vessel coronary disease: Subgroup analysis from the COMBO collaboration

Abstract Background Small vessel diameter is associated with higher risk of target lesion revascularization (TLR) after percutaneous coronary intervention (PCI). The COMBO sirolimus-eluting biodegradable-polymer stent has a proprietary anti-CD34 antibody layer to enhance homogeneous endothelialization, which may be advantageous in treating small vessels. Objective We examined for differences in 1-year clinical outcomes after PCI by maximum implanted stent diameter from the COMBO collaboration. Methods The COMBO collaboration (n = 3614) is a patient-level pooled dataset of patients undergoing PCI with COMBO stents in the MASCOT and REMEDEE multicenter registries. Stent diameter was available in 3590 (99.3%) patients. We compared patients receiving COMBO stents Results The study included 792 (22%) patients with small stents Conclusions One-year ischemic outcomes after COMBO PCI were similar irrespective of stent diameter in this all-comers international cohort.